Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Apr;155(4):1352-4.

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer

F M Debruyne  1 , G A Dijkman, D C Lee, W P Witjes, F del Moral, H F Karthaus, A P van der Mejden, J W Plasman, H C Pull, J J Kums, J G Idema, J W Hoefakker, R P Heijbroek, P J Kil, G S Khoe
Affiliations
  • PMID: 8632572
Free article
Clinical Trial

A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer

F M Debruyne et al. J Urol. 1996 Apr.
Free article

Abstract

Purpose: To assess the pharmacodynamic equivalence of the new 10.8 mg. goserelin depot with the current 3.6 mg. depot 3 studies were performed in patients with advanced prostate cancer.

Materials and methods: In 2 comparative studies 160 patients were randomized for dosing every 12 weeks using the 10.8 mg. depot or every 4 weeks using the 3.6 mg. depot. In the noncomparative study 35 patients received the 10.8 mg. depot. Blood sampling for serum testosterone and evaluation of toxicity was done during the 48-week study period.

Results: Serum testosterone profiles of the 10.8 and 3.6 mg. goserlin depots were similar with testosterone levels decreasing into the castrate range by day 21 after depot administration. The safety profile of 10.8 mg. goserelin is comparable to that of the current monthly depot with the main side effects related to androgen deprivation.

Conclusions: The new long acting depot was pharmacologically equivalent, and well tolerated locally and systemically, and will offer added convenience to patients and health care personnel.

PubMed Disclaimer